KR101415705B1 - 디아자비시클로알칸의 니코틴 아세틸콜린 수용체 서브-타입 선택성 아미드 - Google Patents

디아자비시클로알칸의 니코틴 아세틸콜린 수용체 서브-타입 선택성 아미드 Download PDF

Info

Publication number
KR101415705B1
KR101415705B1 KR1020097008122A KR20097008122A KR101415705B1 KR 101415705 B1 KR101415705 B1 KR 101415705B1 KR 1020097008122 A KR1020097008122 A KR 1020097008122A KR 20097008122 A KR20097008122 A KR 20097008122A KR 101415705 B1 KR101415705 B1 KR 101415705B1
Authority
KR
South Korea
Prior art keywords
diazabicyclo
ylcarbonyl
compounds
octane
chlorofuran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097008122A
Other languages
English (en)
Korean (ko)
Other versions
KR20090074051A (ko
Inventor
아나톨리 마쭈로프
랜 미아오
윈-더 씨아오
필립 에스. 해먼드
크레이그 에이치. 밀러
스리니비사 라오 아키레띠
브이. 스리니바사 무르티
리자이나 씨. 위터커
스콧 알. 브레이닝
매트 에스. 멜빈
Original Assignee
타가셉트 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 타가셉트 인코포레이티드 filed Critical 타가셉트 인코포레이티드
Publication of KR20090074051A publication Critical patent/KR20090074051A/ko
Application granted granted Critical
Publication of KR101415705B1 publication Critical patent/KR101415705B1/ko
Assigned to 어테뉴아, 인크. reassignment 어테뉴아, 인크. 권리의 전부이전등록 Assignors: 카탈리스트 바이오사이언시즈, 인코포레이티드
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020097008122A 2006-11-02 2007-11-01 디아자비시클로알칸의 니코틴 아세틸콜린 수용체 서브-타입 선택성 아미드 Expired - Fee Related KR101415705B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85607906P 2006-11-02 2006-11-02
US60/856,079 2006-11-02
PCT/US2007/083330 WO2008057938A1 (en) 2006-11-02 2007-11-01 Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020107025973A Division KR20100124356A (ko) 2006-11-02 2007-11-01 디아자비시클로알칸의 니코틴 아세틸콜린 수용체 서브-타입 선택성 아미드

Publications (2)

Publication Number Publication Date
KR20090074051A KR20090074051A (ko) 2009-07-03
KR101415705B1 true KR101415705B1 (ko) 2014-07-04

Family

ID=39233054

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097008122A Expired - Fee Related KR101415705B1 (ko) 2006-11-02 2007-11-01 디아자비시클로알칸의 니코틴 아세틸콜린 수용체 서브-타입 선택성 아미드
KR1020107025973A Abandoned KR20100124356A (ko) 2006-11-02 2007-11-01 디아자비시클로알칸의 니코틴 아세틸콜린 수용체 서브-타입 선택성 아미드

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020107025973A Abandoned KR20100124356A (ko) 2006-11-02 2007-11-01 디아자비시클로알칸의 니코틴 아세틸콜린 수용체 서브-타입 선택성 아미드

Country Status (32)

Country Link
US (6) US8114889B2 (https=)
EP (2) EP2284171B1 (https=)
JP (2) JP5539723B2 (https=)
KR (2) KR101415705B1 (https=)
CN (4) CN102838605B (https=)
AR (2) AR063451A1 (https=)
AT (2) ATE509022T1 (https=)
AU (2) AU2007317433B2 (https=)
BR (2) BRPI0717930A2 (https=)
CA (1) CA2663925C (https=)
CL (1) CL2007003155A1 (https=)
CO (1) CO6180435A2 (https=)
CY (1) CY1112374T1 (https=)
DK (1) DK2094703T3 (https=)
ES (2) ES2395212T3 (https=)
HR (1) HRP20110570T1 (https=)
IL (2) IL197618A (https=)
MX (1) MX2009004801A (https=)
MY (2) MY156730A (https=)
NO (1) NO20091251L (https=)
NZ (2) NZ587847A (https=)
PE (2) PE20110671A1 (https=)
PL (1) PL2094703T3 (https=)
PT (1) PT2094703E (https=)
RS (1) RS51834B (https=)
RU (2) RU2448969C2 (https=)
SA (1) SA07280584B1 (https=)
SI (1) SI2094703T1 (https=)
TW (3) TWI405763B (https=)
UA (2) UA98944C2 (https=)
UY (1) UY30686A1 (https=)
WO (1) WO2008057938A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI405763B (zh) * 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
JP2011513421A (ja) * 2008-03-05 2011-04-28 ターガセプト，インコーポレイテッド サブタイプ選択的なジアザビシクロアルカンのアミド
WO2009113950A1 (en) * 2008-03-10 2009-09-17 Astrazeneca Ab Therapeutic combinations of (a) an antipsychotic and (b) an alpha-4/beta-2 (a4b2)-neuronal nicotinic receptor agonist
ES2383246T3 (es) 2008-06-05 2012-06-19 Glaxo Group Limited 4-amino-indazoles
US8658635B2 (en) 2008-06-05 2014-02-25 Glaxosmithkline Intellectual Property Development Limited Benzpyrazol derivatives as inhibitors of PI3 kinases
JP5502076B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規化合物
WO2010028011A1 (en) * 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
WO2010028033A1 (en) * 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclooctanes and uses thereof
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
WO2010125082A1 (en) 2009-04-30 2010-11-04 Glaxo Group Limited Oxazole substituted indazoles as pi3-kinase inhibitors
RU2417082C2 (ru) * 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
DK2513085T3 (en) 2009-11-18 2016-12-05 Suven Life Sciences Ltd Alfa4beta2 bicyclic compounds as nicotinic acetylcholine receptor ligands
BR112012016201A2 (pt) 2009-12-29 2017-12-19 Suven Life Sciences Ltd ''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto''
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
CN105764905B (zh) 2013-11-26 2019-06-07 豪夫迈·罗氏有限公司 新的八氢-环丁二烯并[1，2-c；3，4-c’]二吡咯-2基
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
SG10202011669PA (en) 2014-10-20 2020-12-30 Oyster Point Pharma Inc Methods of treating ocular conditions
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
RU2018112230A (ru) 2015-09-24 2019-10-30 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов atx
KR20180054830A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서의 이환형 화합물
AU2016328365B2 (en) * 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
CR20180057A (es) * 2015-09-24 2018-04-02 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
CN109310692B (zh) 2016-04-07 2022-01-25 奥伊斯特普安生物制药公司 治疗眼部病状的方法
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
SG11201908560SA (en) 2017-03-16 2019-10-30 Hoffmann La Roche Heterocyclic compounds useful as dual atx/ca inhibitors
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
US20220378756A1 (en) 2019-09-19 2022-12-01 Forma Therapeutics, Inc. Activating pyruvate kinase r
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016616A1 (en) 2002-08-14 2004-02-26 Astrazeneca Ab Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists.
WO2004076453A1 (en) 2003-02-27 2004-09-10 Neurosearch A/S Novel diazabicyclic aryl derivatives

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5468858A (en) 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
CZ282567B6 (cs) * 1993-12-29 1997-08-13 Pfizer Inc. Diazabicyklické sloučeniny a farmaceutické prostředky na jejich bázi
US5457121A (en) 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
MXPA02005884A (es) * 1999-12-14 2002-10-23 Neurosearch As Heteroaril-diazabicicloalcanos novedosos.
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
CA2440803A1 (en) 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
MXPA04000012A (es) 2001-07-06 2004-05-21 Neurosearch As Compuestos novedosos, su preparacion y uso.
SE0202430D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
CN1317280C (zh) * 2003-02-27 2007-05-23 神经研究公司 新的二氮杂双环芳基衍生物
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US7365193B2 (en) * 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
RU2006146608A (ru) * 2004-06-09 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) ОКТАГИДРОПИРРОЛО[3,4-с]-ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ АГЕНТОВ
EP1781670A1 (en) 2004-07-22 2007-05-09 Cumbre Pharmaceuticals Inc. Rifamycin derivatives for treating microbial infections
US20060258672A1 (en) * 2005-05-13 2006-11-16 Joseph Barbosa Multicyclic compounds and methods of their use
TWI405763B (zh) * 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016616A1 (en) 2002-08-14 2004-02-26 Astrazeneca Ab Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists.
WO2004076453A1 (en) 2003-02-27 2004-09-10 Neurosearch A/S Novel diazabicyclic aryl derivatives

Also Published As

Publication number Publication date
BRPI0717930A2 (pt) 2011-05-10
ES2395212T3 (es) 2013-02-11
IL209026A (en) 2014-03-31
US8859609B2 (en) 2014-10-14
CO6180435A2 (es) 2010-07-19
CA2663925C (en) 2015-04-21
US9580434B2 (en) 2017-02-28
US20120289572A1 (en) 2012-11-15
MY145602A (en) 2012-03-15
ATE509022T1 (de) 2011-05-15
CN102020646A (zh) 2011-04-20
RU2517693C2 (ru) 2014-05-27
US8114889B2 (en) 2012-02-14
IL197618A (en) 2013-09-30
PL2094703T3 (pl) 2011-10-31
NZ587847A (en) 2011-09-30
RU2009120674A (ru) 2010-12-10
PT2094703E (pt) 2011-07-22
BRPI0722387A2 (pt) 2023-02-23
PE20110671A1 (es) 2011-10-20
CN102838605B (zh) 2017-04-26
US20130005789A1 (en) 2013-01-03
AU2010219323B2 (en) 2012-05-03
CN101528745A (zh) 2009-09-09
AU2007317433A1 (en) 2008-05-15
DK2094703T3 (da) 2011-08-29
ES2395157T3 (es) 2013-02-08
KR20100124356A (ko) 2010-11-26
RU2009138600A (ru) 2011-04-27
AU2007317433B2 (en) 2012-05-10
HK1133260A1 (en) 2010-03-19
AR063451A1 (es) 2009-01-28
CN102020646B (zh) 2013-11-13
KR20090074051A (ko) 2009-07-03
AU2010219323A1 (en) 2010-09-30
TWI405763B (zh) 2013-08-21
HK1149751A1 (en) 2011-10-14
NO20091251L (no) 2009-05-28
WO2008057938A1 (en) 2008-05-15
CL2007003155A1 (es) 2008-05-16
PE20081441A1 (es) 2008-10-30
TW201305176A (zh) 2013-02-01
IL209026A0 (en) 2011-01-31
JP2010509230A (ja) 2010-03-25
MY156730A (en) 2016-03-15
AR079840A2 (es) 2012-02-22
ATE545646T1 (de) 2012-03-15
US8921410B2 (en) 2014-12-30
HRP20110570T1 (hr) 2011-09-30
CN102942569B (zh) 2015-10-28
JP5739398B2 (ja) 2015-06-24
JP5539723B2 (ja) 2014-07-02
EP2284171A1 (en) 2011-02-16
EP2094703A1 (en) 2009-09-02
MX2009004801A (es) 2009-07-31
CA2663925A1 (en) 2008-05-15
TWI454262B (zh) 2014-10-01
EP2094703B1 (en) 2011-05-11
CY1112374T1 (el) 2015-12-09
US20100173932A1 (en) 2010-07-08
RU2448969C2 (ru) 2012-04-27
UA106718C2 (uk) 2014-10-10
EP2284171B1 (en) 2012-02-15
TW201114424A (en) 2011-05-01
UA98944C2 (ru) 2012-07-10
US20100081683A1 (en) 2010-04-01
SI2094703T1 (sl) 2011-07-29
US20150080576A1 (en) 2015-03-19
TWI404532B (zh) 2013-08-11
TW200826935A (en) 2008-07-01
RS51834B (sr) 2012-02-29
NZ575557A (en) 2011-01-28
US20160039833A1 (en) 2016-02-11
US8268860B2 (en) 2012-09-18
UY30686A1 (es) 2009-08-03
CN101528745B (zh) 2011-09-14
CN102942569A (zh) 2013-02-27
IL197618A0 (en) 2009-12-24
SA07280584B1 (ar) 2010-11-02
CN102838605A (zh) 2012-12-26
JP2013056919A (ja) 2013-03-28

Similar Documents

Publication Publication Date Title
KR101415705B1 (ko) 디아자비시클로알칸의 니코틴 아세틸콜린 수용체 서브-타입 선택성 아미드
AU2012205208A1 (en) Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes
HK1149751B (en) Amides of diazabicycloalkanes selective for nicotinic acetylcholine receptor sub-types
HK1133260B (en) Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20170621

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20181204

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230701

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230701